NCT07200076

Comparison of Mean Duration of Post Operative Analgesia Following QL-2 Block vs QL-3 Block Using Ropivacain 0.25% in Patients Undergoing Unilateral Inguinal Hernia Repair

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Quaid-e-Azam Medical College · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

To compare the mean dulation of post operative analgesia following QL2 block (posterior quadratus lumborum block) and the QL3 block (transmuscular quadratus lumborum block) using ropivacaine 0.25% in patients undergoing unilateral inguinai hernia repair. Rationale of the proposed study is to find an optimal approach for quadratus lumborum block (QLB) in the context of local population as no local study has already been carried out for our population. The study seeks to determine which approach provides superior postoperative pain relief and aspires to establish a clear rationale for the application of one technique over the other in local population. By uncovering the strengths and limitations of each approach, the study intends to guide local clinicians in making informed decisions for optimizing postoperative pain management strategies. The outcomes of this study are anticipated to have a substantial impact on clinical practice, potentially leading to improved patient outcomes, reduced opioid consumption, and enhanced patient comfort following inguinal hernia repair surgeries in local settings.

Conditions

• Inguinal Hernia Unilateral

Interventions

Type	Name	Description
PROCEDURE	Quadratus Lumborum (QL) Block	In the QLB-2 approach, a needle will be inserted in-plane from anterior to posterior, directed towards the posterior QL muscle border, and a 20 ml solution of 0.25% ropivacaine will be injected. For the QLB-3 approach, the needle will be inserted in-plane from anterior to posterior, traversing the QL muscle's proper fascia to target the plane between the QL and PM muscles, and a 20 ml solution of 0.25% ropivacaine will be injected.

Timeline

• Start date: 2024-07-01
• Primary completion: 2024-12-30
• Completion: 2025-01-28
• First posted: 2025-09-30
• Last updated: 2025-10-06

Locations

1 site across 1 country: Pakistan